Literature DB >> 29261627

Incidental Detection of Medullary Thyroid Carcinoma by 68Ga-DOTATATE PET/CT in a Patient With Neuroendocrine Tumor Liver Metastases.

Sonia Mahajan, Ashok Shaha, Ravinder K Grewal.   

Abstract

Ga-DOTATATE, a positron-emitting somatostatin analog, has been approved by the Food and Drug Administration for imaging neuroendocrine tumors (NETs). The presence of a second primary malignancy is common in NETs; however, synchronous primary malignancy in the thyroid has rarely been reported. The value of Ga-DOTATATE in medullary thyroid cancer is being investigated and is currently recommended for use when treatment with somatostatin analogs is an option. We present a 55-year-old man with abdominal pain associated with well-differentiated NET liver metastases and incidental medullary thyroid carcinoma demonstrated on a Ga-DOTATATE PET/CT.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29261627      PMCID： PMC5752440          DOI： 10.1097/RLU.0000000000001950

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN： 0363-9762            Impact factor:   7.794


  10 in total

1.  The Impact of 68Ga-DOTATATE PET/CT Imaging on Management of Patients with Neuroendocrine Tumors: Experience from a National Referral Center in the United Kingdom.

Authors:  Evangelia Skoura; Sofia Michopoulou; Mullan Mohmaduvesh; Emmanouil Panagiotidis; Mohammed Al Harbi; Christos Toumpanakis; Omar Almukhailed; Irfan Kayani; Rizwan Syed; Shaunak Navalkissoor; Peter J Ell; Martyn E Caplin; Jamshed Bomanji
Journal:  J Nucl Med       Date:  2015-10-15       Impact factor: 10.057

Review 2.  Incidence of Second Primary Malignancies in Patients with Neuroendocrine Tumours.

Authors:  Ashley K Clift; Panagiotis Drymousis; Adil Al-Nahhas; Harpreet Wasan; John Martin; Sture Holm; Andrea Frilling
Journal:  Neuroendocrinology       Date:  2015-03-21       Impact factor: 4.914

3.  Most of the Intended Management Changes After 68Ga-DOTATATE PET/CT Are Implemented.

Authors:  Jeremie Calais; Johannes Czernin; Matthias Eiber; Wolfgang P Fendler; Jeannine Gartmann; Anthony P Heaney; Andrew E Hendifar; Joseph R Pisegna; J Randolph Hecht; Edward M Wolin; Roger Slavik; Pawan Gupta; Andrew Quon; Christiaan Schiepers; Martin S Allen-Auerbach; Ken Herrmann
Journal:  J Nucl Med       Date:  2017-05-04       Impact factor: 10.057

4.  Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives.

Authors:  Maria Chiara Zatelli; Daniela Piccin; Federico Tagliati; Arianna Bottoni; Andrea Luchin; Cristina Vignali; Angelo Margutti; Marta Bondanelli; Gian Carlo Pansini; Maria Rosa Pelizzo; Michael D Culler; Ettore C Degli Uberti
Journal:  J Clin Endocrinol Metab       Date:  2006-03-28       Impact factor: 5.958

5.  Occurrence of second primary malignancies in patients with neuroendocrine tumors of the digestive tract and pancreas.

Authors:  Kimberly Kamp; Ronald A M Damhuis; Richard A Feelders; Wouter W de Herder
Journal:  Endocr Relat Cancer       Date:  2012-02-13       Impact factor: 5.678

6.  The risk of metachronous cancers in patients with small-intestinal carcinoid tumors: a US population-based study.

Authors:  Sunil Amin; Richard R P Warner; Steven H Itzkowitz; Michelle Kang Kim
Journal:  Endocr Relat Cancer       Date:  2012-05-24       Impact factor: 5.678

7.  Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA.

Authors:  Murat Fani Bozkurt; Irene Virgolini; Sona Balogova; Mohsen Beheshti; Domenico Rubello; Clemens Decristoforo; Valentina Ambrosini; Andreas Kjaer; Roberto Delgado-Bolton; Jolanta Kunikowska; Wim J G Oyen; Arturo Chiti; Francesco Giammarile; Anders Sundin; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-25       Impact factor: 9.236

8.  Impact of 68Ga-DOTATATE PET/CT on the management of neuroendocrine tumors: the referring physician's perspective.

Authors:  Ken Herrmann; Johannes Czernin; Edward M Wolin; Pawan Gupta; Martin Barrio; Antonio Gutierrez; Christiaan Schiepers; Sherly Mosessian; Michael E Phelps; Martin S Allen-Auerbach
Journal:  J Nucl Med       Date:  2014-12-11       Impact factor: 10.057

9.  Neuroendocrine tumors and second primary malignancy--a relationship with clinical impact?

Authors:  Rupert Prommegger; Christian Ensinger; Philipp Steiner; Tonja Sauper; Christoph Profanter; Raimund Margreiter
Journal:  Anticancer Res       Date:  2004 Mar-Apr       Impact factor: 2.480

10.  Second cancers in patients with neuroendocrine tumors.

Authors:  Hui-Jen Tsai; Chun-Chieh Wu; Chia-Rung Tsai; Sheng-Fung Lin; Li-Tzong Chen; Jeffrey S Chang
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240
  10 in total
  1 in total

Review 1.  Prevalence and significance of incidental findings on 68 Ga-DOTA-conjugated somatostatin receptor-targeting peptide PET/CT: a systematic review of the literature.

Authors:  Morten Bentestuen; Farid Gossili; Charlotte Elberling Almasi; Helle Damgaard Zacho
Journal:  Cancer Imaging       Date:  2022-09-03       Impact factor: 5.605
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.